An update from Altimmune ( (ALT) ) is now available.
Altimmune, Inc. has appointed Gregory Weaver as Chief Financial Officer, bringing his extensive experience in finance to the company as it advances its lead program, pemvidutide. With a history in capital market transactions and product launches, Weaver’s expertise is expected to play a crucial role in Altimmune’s strategic growth. His appointment comes at a pivotal moment as Altimmune focuses on developing innovative therapeutics for metabolic disorders.
See more insights into ALT stock on TipRanks’ Stock Analysis page.